Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Shnaghai Shengkang Medical Center

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03334474
Recruitment Status : Not yet recruiting
First Posted : November 7, 2017
Last Update Posted : November 7, 2017
Sponsor:
Information provided by (Responsible Party):
Guoxiang Fu, Shanghai Jiao Tong University Affiliated Sixth People’s Hospital

Brief Summary:
The process of population aging that is occurring in developed societies represents a major challenge for the health system. The aim of this study is to analyze factors that have an influence on early vascular aging (EVA), estimated by carotid-femoral pulse wave velocity (cf-PWV) and Cardio Ankle Vascular Index (CAVI), and to determine differences by gender in a Chinese population.

Condition or disease
Vascular Diseases

Layout table for study information
Study Type : Observational
Estimated Enrollment : 1000 participants
Observational Model: Case-Only
Time Perspective: Cross-Sectional
Official Title: Shnaghai Shengkang Medical Center
Estimated Study Start Date : February 1, 2018
Estimated Primary Completion Date : February 1, 2021
Estimated Study Completion Date : May 1, 2021

Group/Cohort
young
18-35 years old
middle
35-65 years old
aged
65-85 years old



Primary Outcome Measures :
  1. Cardio-ankle vascular index [ Time Frame: 2 years ]
    This parameter will be estimated using Vasera device VS-1500.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 85 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population
Study population It will be the urban population attached to the Health Center of Shanghai. Using a random sampling stratified by age groups and gender, 300 subjects will be selected in each group (150 males and 150 females), aged 35 to 85 years.
Criteria

Inclusion Criteria:

  • • Patients aged 35 to 85 years who agree to participate in the study and do not meet any of the exclusion criteria.

Exclusion Criteria:

  • • Subjects who are in terminal condition, who cannot travel to the health centers to undergo the corresponding examinations, and those who do not wish to sign the informed consent.

    • Subjects with a history of CVD (ischemic heart disease or stroke, peripheral arterial disease or heart failure), diagnosed renal failure in terminal stages (glomerular filtration rate below 30%), chronic inflammatory disease, or acute inflammatory process in the past three months.
    • Patients treated with estrogens, testosterone, or growth hormone.
Layout table for additonal information
Responsible Party: Guoxiang Fu, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai Jiao Tong University Affiliated Sixth People’s Hospital
ClinicalTrials.gov Identifier: NCT03334474    
Other Study ID Numbers: shengkang
First Posted: November 7, 2017    Key Record Dates
Last Update Posted: November 7, 2017
Last Verified: November 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Vascular Diseases
Cardiovascular Diseases